Busulfan is an alkylating agent currently used in the myeloablative conditioning regimen before stem cell transplantation. Its mechanism of action is not fully understood, nor the reason for its ...

Records collected as part of routine clinical busulfan monitoring between April 1991 and September 1998 at the Fred Hutchinson Cancer Research Center were examined retrospectively. Inclusion required ...

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials We performed an open-label, randomized ...

The Fred Hutch Pharmacokinetics Laboratory (PK Lab) is a CAP/CLIA-certified clinical lab that provides therapeutic drug monitoring (TDM) services. We specialize in busulfan TDM, providing ...

HOUSTON — Using a treosulfan-based myeloablative regimen in place of one based on busulfan may improve survival in vulnerable patients with acute myeloid leukemia (AML) and myelodysplastic syndrome ...

Allogeneic hematopoietic stem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails to reconstitute immunity associated with T cells, B cells, and natural killer (NK ...

It remains controversial whether busulfan-based versus total body irradiation (TBI)–based regimens have comparable outcomes in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic ...

Please provide your email address to receive an email when new articles are posted on . Myeloablative fludarabine and busulfan conditioning appeared effective for patients with myelofibrosis ...

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals Inc. announced today the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company's AP-rated therapeutic ...

Details concerning the Busulfan (2mg) medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and ...